Abstract. Clinical diagnosis of Alzheimer's disease (AD) relying on symptomatic features has a low specificity, emphasizing the importance of the pragmatic use of neurochemical biomarkers. The most advanced and reliable markers are amyloid-␤ (A␤ 42 ), total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) with relatively high levels of sensitivity, specificity, and diagnostic accuracy. Recent advances within the field of proteomics offer the potential to search for novel biomarkers in CSF by using modern methods, such as microarrays. The purpose of this study was to identify pathognostic proteins in CSF obtained from patients whose clinical AD diagnosis was confirmed by the "core" biomarkers. CSF samples were obtained from 25 AD patients and 25 control individuals. The levels of A␤ 42 , t-tau, and p-tau were measured by ELISA. In the microarray experiments, ultrasensitive slides representing of 653 antigens were used. Apolipoprotein E genotyping was also determined. A decrease of seven CSF proteins in AD were found, four of them (POLG, MGMT, parkin, and ApoD) have a protective function against neuronal death, while the remaining three proteins (PAR-4, granzyme B, Cdk5) trigger multiple pathways facilitating neuronal cell death. Since these proteins from CSF samples could not be identified by western blot, their decreased levels in AD patients were not verified. Our results provide new information of pathognostic importance of POLG and granzyme B in AD. Although the function of MGMT, parkin, ApoD, PAR-4, and Cdk5 was previously known in AD, the findings presented here provide novel evidence of the significance of CSF analysis in the mapping of the AD pathomechanism.
INTRODUCTION

26
Alzheimer's disease (AD) is a neurodegenera- The clinical diagnosis of AD during life is difficult, were used to analyze ApoE alleles.
143
Peptide microarray analysis 144 Master Antibody Microarray (Spring BioScience ® ,
145
Cat. # AMS-700) was used to perform antibody array 146 studies, according to the manufacturer's instructions.
147
The specific antibodies were covalently immobilized 148 on glass surface coated with 3D polymer materials to It was centrifuged at 14000 × g for 5 min at 4 • C.
164
The resulted protein pellet was resuspended in 50 l 
213
RESULTS
214
To confirm the clinical diagnoses of AD, the levels AD group compared with control probands (Fig. 1 The numbers represent the ratio of pixel intensities derived from 5 control and 5 Alzheimer's disease independent microarrays. One microarray sample was a pooled construction of 5 individual CSF samples derived from control or Alzheimer's disease groups, respectively. Molecular weight and function of the seven proteins are also presented. AD, Alzheimer's disease; POLG, DNA polymerase gamma; MGMT, methylated-DNA-protein-cysteine methyltransferase; ApoD, apolipoprotein D; PAR-4, protein kinase C apoptosis WT1 regulator protein; Cdk5, cyclin-dependent kinase 5; S.E.M., standard error of mean; CSF, cerebrospinal fluid. tion of ApoD levels in the CSF of AD patients (Fig. 4) .
330
These various results can be explained with not only the (Fig. 4) , it was initially identified to be asso- 
378
Another protein which decreased in CSF obtained 379 from AD patients was Cdk5 ( 
